Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Jones Report is very good

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Nov 30, 2022 1:00pm

201 Views

Post# 35140224

RE:RE:Jones Report is very good

Here is a snippet from the report I thought you might like seeing JFM:

"With this said, the PDC field has advanced more slowly than the ADC field. PDCs bearing

radioactive payloads have seen the most success and include Novartis’ beta-emitting

therapeutic Lutathera and imaging agents In-111-DTPA-octreotide and Ga-68-DOTATATE. The

only other FDA approved PDC, Oncopeptides AB’s Pepaxto was withdrawn from the U.S. market

in October 2021 after less than a year following a poor overall survival rate reported in its Phase

III trial in multiple myeloma."

jfm1330 wrote: I think that the only way they were able to get two analysts to write reports on Thera is because they were able to convinced them that really good news were coming up relatively quickly, which they were not in position to do previously.

Also, if Thera was willing to convince these analysts, it's because they think they will be able to deliver these good news. At least, that's the way I see it because those reports will be pointless if good news are not following them. So why would the management push to convince these analysts if they have nothing really positive to announce in the next two or three months?

If their plan is logic, get analysts in first, then really good news, then financing and possible partnerships. Again, a strong proof of concept would push the stock up a lot, because it would allow Levesque to be very promotional about the potential of the company. It would no longer be only TH1902. It would be SORT1+ platform with many possibilities to develop new PDCs.

SPCEO1 wrote: I had a chance to look at it more closely and it is the best report ever done on TH in my opinion. Very strong info and analysis on the cancer side of the equation which is all important. Great, very comprehensive work on the financial statement projections out to 2030 and good valuation analysis. Who would have thought the retail broker would put out the best report on TH? Not me.

He is projecting share issuance of $50 million in 2023, $50 million in 2024 and $100 million in 2025, likely to go along with clinical success with TH-1902.

I am not sure how things work with these retail brokers but there was obviously no immediate reaction to this excellent report by the market. If they are able to get their clients engaged with the stock, however, it could have a big impact.